REPROCELL News

Lantern Pharma a clinical stage oncology biotech leveraging A.I. and machine learning genomics company has selected REPROCELL Inc. to provide drug screening and drug sensitivity services.

Continue reading →

Drug Discovery news, Cancer Research, Preclinical


Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.

Continue reading →

Drug Discovery news, Human Tissues, MEA testing, Cardiac Research


On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance.  He was also joined by:

• Dr Diane Harbison, CEO, of Stratified Medicine Scotland

• Claire Mack, CEO, of Scottish Renewables

• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK

Continue reading →

Drug Discovery news, Research and Development, Open Government Partnership, SME


REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday, at https://www.dur.ac.uk/news/newsitem/?itemno=33385

Continue reading →

Drug Discovery news, Human Tissues, 3D Cell Model, Bio-engineered Tissue Models